Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 698,982
  • Shares Outstanding, K 88,929
  • Annual Sales, $ 5,280 K
  • Annual Income, $ -94,940 K
  • 60-Month Beta 1.89
  • Price/Sales 130.51
  • Price/Cash Flow N/A
  • Price/Book 4.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.29
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +34.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.80 +35.52%
on 05/01/20
8.18 -3.91%
on 05/20/20
+1.04 (+15.25%)
since 04/22/20
3-Month
4.22 +86.26%
on 03/18/20
8.18 -3.91%
on 05/20/20
-0.16 (-2.00%)
since 02/21/20
52-Week
2.10 +274.29%
on 08/15/19
8.81 -10.83%
on 02/20/20
+5.05 (+179.72%)
since 05/22/19

Most Recent Stories

More News
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular...

ARDX : 7.86 (+1.42%)
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer

, /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular...

ARDX : 7.86 (+1.42%)
Will Ardelyx Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Ardelyx

ARDX : 7.86 (+1.42%)
Ardelyx (ARDX) Upgraded to Strong Buy: Here's Why

Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ARDX : 7.86 (+1.42%)
Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights

, /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular...

ARDX : 7.86 (+1.42%)
Here's Why Momentum Investors Will Love Ardelyx (ARDX)

Does Ardelyx (ARDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

ARDX : 7.86 (+1.42%)
Knight Therapeutics Announces Approval of IBSRELA(TM) in Canada

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced that Health Canada has approved IBSRELA(TM) (tenapanor) for the treatment of irritable...

KHTRF : 5.4720 (+1.00%)
GUD.TO : 7.50 (+0.81%)
ARDX : 7.86 (+1.42%)
Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors

Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced...

ARDX : 7.86 (+1.42%)
Ardelyx Inc is Among the Companies in the Biotechnology Industry with the Best Relative Performance (ARDX , RTRX , AMAG , RGEN , EXAS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AMAG : 7.93 (+6.16%)
ARDX : 7.86 (+1.42%)
RTRX : 16.66 (unch)
Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 221.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ARDX : 7.86 (+1.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ARDX with:

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

2nd Resistance Point 8.09
1st Resistance Point 7.97
Last Price 7.86
1st Support Level 7.68
2nd Support Level 7.51

See More

52-Week High 8.81
Last Price 7.86
Fibonacci 61.8% 6.25
Fibonacci 50% 5.46
Fibonacci 38.2% 4.67
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar